PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Moreau, P. [1 ]
Chanan-Khan, A. [2 ]
Roberts, A. W. [3 ]
Agarwal, A. [4 ]
Facon, T. [5 ]
Kumar, S. [2 ]
Touzeau, C. [1 ]
Diehl, S. [6 ]
Cordero, J. [6 ]
Ross, J. [6 ]
Munasinghe, W. [6 ]
Zhu, M. [6 ]
Salem, A. H. [6 ]
Leverson, J. [6 ]
Maciag, P. [6 ]
Verdugo, M. [6 ]
Harrison, S. J. [7 ]
机构：
[1] CHU Nantes, Hotel Dieu HME, Nantes, France
[2] Mayo Clin, Rochester, MN USA
[3] Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ Arizona, Ctr Canc, Tucson, AZ USA
[5] Hop Huriez, CHRU Lille, Lille, France
[6] AbbVie Inc, N Chicago, IL USA
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P272
引用
收藏
页码：81 / 82
页数：2
相关论文
共 50 条
  • [31] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Yasuo Mori
    Ilseung Choi
    Goichi Yoshimoto
    Tsuyoshi Muta
    Satoshi Yamasaki
    Kazuki Tanimoto
    Tomohiko Kamimura
    Hiromi Iwasaki
    Ryosuke Ogawa
    Koichi Akashi
    Toshihiro Miyamoto
    International Journal of Hematology, 2020, 111 : 673 - 680
  • [32] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Victoria Mateos, Maria
    Prosper, Felipe
    Martin Sanchez, Jesus
    Ocio, Enrique M.
    Oriol, Albert
    Motllo, Cristina
    Michot, Jean-Marie
    Jarque, Isidro
    Iglesias, Rebeca
    Sole, Maria
    Martinez, Sara
    Kahatt, Carmen
    Fudio, Salvador
    Corral, Gema
    Zeaiter, Ali
    Montilla, Lola
    Ribrag, Vincent
    CANCER MEDICINE, 2023, 12 (04): : 3999 - 4009
  • [33] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Mori, Yasuo
    Choi, Ilseung
    Yoshimoto, Goichi
    Muta, Tsuyoshi
    Yamasaki, Satoshi
    Tanimoto, Kazuki
    Kamimura, Tomohiko
    Iwasaki, Hiromi
    Ogawa, Ryosuke
    Akashi, Koichi
    Miyamoto, Toshihiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 673 - 680
  • [34] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib plus dexamethasone in relapsed and relapsed/refractory multiple myeloma
    Laubach, Jacob P.
    Tuchman, Sascha A.
    Rosenblatt, Jacalyn M.
    Mitsiades, Constantine S.
    Colson, Kathleen
    Masone, Kelly
    Warren, Diane
    Redd, Robert A.
    Grayson, Dena
    Richardson, Paul G.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [35] Bortezomib asociated to dexamethasone in patients with relapsed/refractory multiple myeloma
    de la O, G. M. Maria
    Garcia-Delgado, R.
    Cuesta, M. A.
    Garrido, P.
    Dominguez, B.
    Hernandez, F.
    Galan, M.
    Sanchez, A.
    Garcia-Sanchez, R.
    Lopez, E.
    Perez, E.
    Bailen, A.
    Heiniger, A. I.
    Ramirez, G.
    Garcia, A.
    Jurado, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 482 - 483
  • [36] Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
    Touzeau, Cyrille
    Chanan-Khan, Asher Alban Akmal
    Roberts, Andrew Warwick
    Agarwal, Amit
    Facon, Thierry
    Lebovic, Daniel
    Moreau, Philippe
    Darden, David E.
    Morris, Lura J.
    Ross, Jeremy A.
    Salem, Ahmed H.
    Munasinghe, Wijith
    Zhu, Ming
    Leverson, Joel
    Enschede, Sari H.
    Humerickhouse, Rod
    Harrison, Simon J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Pareto, A. E.
    Zacheo, I.
    Di Perna, M.
    Nappi, D.
    Peluso, I.
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : S116 - S117
  • [38] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Costa, Luciano J.
    Stadtmauer, Edward Allen
    Morgan, Gareth John
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej J.
    Mobasher, Mehrdad
    Freise, Kevin
    Ross, Jeremy A.
    Pesko, John Carl
    Munasinghe, Wijith
    Cordero, Jaclyn
    Morris, Lura
    Maciag, Paulo Cesar
    Bueno, Orlando
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
    Bahlis, Nizar J.
    Baz, Rachid
    Harrison, Simon J.
    Quach, Hang
    Ho, Shir-Jing
    Vangsted, Annette Juul
    Plesner, Torben
    Moreau, Philippe
    Gibbs, Simon D.
    Coppola, Sheryl
    Yang, Xiaoqing
    Al Masud, Abdullah
    Ross, Jeremy A.
    Bueno, Orlando
    Kaufman, Jonathan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (32) : 3602 - +
  • [40] Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji
    Harrison, Simon J.
    Cavo, Michele
    de la Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina J.
    Hungria, Vania
    Salwender, Hans
    Suzuki, Kenshi
    Kim, Inho
    Onishi, Maika
    Ku, Grace
    Pothacamury, Rajvineeth Kumar
    Sehgal, Vasudha
    Masud, Abdullah A.
    Ross, Jeremy A.
    Dobkowska, Edyta
    Moreau, Philippe
    BLOOD, 2021, 138
12345